Novartis (NYSE:NVS) (OTCPK:NVSEF) has expanded its collaboration with Argo Biopharma, with multi-asset license and option agreements worth up to $5.2B with the Chinese biotech for several ...
Hosted on MSN
Novartis signs up to $5.2 billion licensing deal with China's biotech Argo for heart drugs
(Reuters) -Swiss drugmaker Novartis has signed an up to $5.2 billion licensing and options deal with Argo Biopharmaceutical for its experimental candidates that target cardiovascular diseases, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback